CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Vaishali Pharma launches Vitamin C supplements to boost immunity
Apurva Joshi
/ Categories: Trending

Vaishali Pharma launches Vitamin C supplements to boost immunity

Vaishali Pharma Limited has launched Vipravita C (Vitamin C supplements) for domestic as well as international market to boost immunity against various prevailing diseases. These supplements are available in different variants like Vitamin C chewable tablets, Vitamin C effervescent tablets and Vitamin C with zinc combo.

Vitamin C is beneficial in many contexts like boosting antioxidant levels, lowering blood pressure, protecting against gout attacks, improving iron absorption, reducing heart disease as well as dementia risk, other than boosting immunity.

Boosting one's immunity system has become the need of the hour, especially during this COVID-19 pandemic situation. The company has a strong portfolio of immunity products and plans to double the product range in the coming years. In April, to fight against the pandemic, the company had launched personal care and hygiene products, such as sanitisers, personal protective equipment (PPE), face shields and face masks.

It has also been seeking product registrations in various countries along with certain approvals, which are currently under the pipeline. Currently, it has over 80 formulation brands marketed in multiple countries and also, built a robust pipeline of around 250 dossiers (with around 120 approvals).

Earlier in June, the company had forayed into the dermatology therapy segment by launching two anti-fungal brands. It already had a strong base in export markets and with this launch, it will now be able to strengthen its position even in the domestic markets.

On Tuesday, the stock of Vaishali Pharma opened 2.2 per cent higher at Rs 51.45 from its previous close of Rs 50.35 on NSE. During the day, it slipped by 4.3 per cent making an intraday low of Rs 48.20. Later, it got closed at Rs 49.

Previous Article Cipla gets USFDA nod for Icatibant Injectable
Next Article Sensex tanks by more than 600 points; IndusInd Bank declines by over 5 per cent
Print
1238 Rate this article:
3.4
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR